A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy

Heather Villarreal, Kathryn H. Dao

Research output: Contribution to journalArticlepeer-review

Abstract

Polymyalgia rheumatica is a disease characterized by systemic inflammation of the proximal muscles and pain in the hips and shoulders, but when this disease occurs contemporaneously with malignancy, there is a possibility of it being a paraneoplastic syndrome. With the advent of immunotherapies to treat various cancers, immune-related adverse events from these therapies are recognized as de novo findings or as flares of an underlying existing rheumatic disease. In this report, we present a case of polymyalgia rheumatica presenting as a paraneoplastic syndrome that was exacerbated during therapy with immune checkpoint inhibitors for recurrent melanoma.

Original languageEnglish (US)
Pages (from-to)124-125
Number of pages2
JournalBaylor University Medical Center Proceedings
Volume34
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Immune checkpoint inhibitor
  • immune-related adverse event
  • ipilimumab
  • melanoma
  • nivolumab
  • paraneoplastic syndrome
  • polymyalgia rheumatica

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy'. Together they form a unique fingerprint.

Cite this